Cargando…
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are promising treatment options for spontaneous cancers in dogs. To optimize the clinical benefit of ICIs, combination therapy with radiation has been proposed for human cancers; however, the safety and efficacy of the combination approach have not...
Autores principales: | Deguchi, Tatsuya, Maekawa, Naoya, Konnai, Satoru, Owaki, Ryo, Hosoya, Kenji, Morishita, Keitaro, Nakamura, Motoji, Okagawa, Tomohiro, Takeuchi, Hiroto, Kim, Sangho, Kinoshita, Ryohei, Tachibana, Yurika, Yokokawa, Madoka, Takagi, Satoshi, Kato, Yukinari, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252299/ https://www.ncbi.nlm.nih.gov/pubmed/37296981 http://dx.doi.org/10.3390/cancers15113013 |
Ejemplares similares
-
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
por: Maekawa, Naoya, et al.
Publicado: (2023) -
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
por: Maekawa, Naoya, et al.
Publicado: (2022) -
Canine Transforming Growth Factor-β Receptor 2-Ig: A Potential Candidate Biologic for Melanoma Treatment That Reverses Transforming Growth Factor-β1 Immunosuppression
por: Takeuchi, Hiroto, et al.
Publicado: (2021) -
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021) -
Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
por: WATARI, Kei, et al.
Publicado: (2021)